Our medical and scientific team continues research to improve therapies and offer additional treatment options. Contact a BioXcellerator Patient Advocate to see if new treatments are available for your condition.

Schedule Your Free Consultation

 Free Consultation

Clinical Studies

December 31, 2022

Mesenchymal Stem Cells for Degenerative Disc Disease

LEARN MORE

December 21, 2022

Mesenchymal Stem Cells for Spinal Cord Injury (SCI)

LEARN MORE

December 12, 2022

Mesenchymal Stem Cells for Knee Osteoarthritis

LEARN MORE

The content on our site, blog posts, educational materials, app, promotional newsletters, and any other written content are not intended to replace an evaluation with a qualified healthcare professional and are not intended as medical advice.

Citations and Scientific References

Orthopedic

  • Looi, Qi Hao and Eng, Sue Ping and Liau, Ling Ling and Tor, Yin Sim and Mohd, Yazid Bajuri, and Ng, Min Hwei and Law, Jia Xian. Mesenchymal stem cell therapy for sports injuries – from research to clinical practice. Sains Malaysiana;2020.49(4):825-38. Available from: http://journalarticle.ukm.my/15354/
  • ​Trebinjac S, Gharairi M. Mesenchymal Stem Cells for Treatment of Tendon and Ligament Injuries-clinical Evidence. Med Arch. 2020 Oct;74(5):387-390. doi: 10.5455/medarh.2020.74.387-390. 
  • ​Kader N, Asopa V, Baryeh K, Sochart D, Maffulli N, Kader D. Cell-based therapy in soft tissue sports injuries of the knee: a systematic review. Expert Opin Biol Ther. 2021 Aug;21(8):1035-1047. doi: 10.1080/14712598.2021.1872538.
  • ​Baryeh K, Asopa V, Kader N, Caplan N, Maffulli N, Kader D. Cell-based therapies for the treatment of sports injuries of the upper limb. Expert Opinion on Biological Therapy. 2021;21(12):1561-74. DOI: 10.1080/14712598.2021.1928630
  • ​Stewart C. Stem cells and regenerative medicine in sport science. Emerg Top Life Sci. 2021;5(4): 563–73. doi: https://doi.org/10.1042/ETLS20210014
  • ​Song Y, Zhang J, Xu H, Lin Z, Chang H, Liu W, Kong L. Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis. J Orthop Translat. 2020 Apr 27;24:121-130. doi: 10.1016/j.jot.2020.03.015.
  • ​Cho WS, Chung SG, Kim W, Jo CH, Lee SU, Lee SY. Mesenchymal Stem Cells Use in the Treatment of Tendon Disorders: A Systematic Review and Meta-Analysis of Prospective Clinical Studies. Ann Rehabil Med. 2021 Aug;45(4):274-283. doi: 10.5535/arm.21078.

Osteoarticular Conditions and Degenerative Disc Disease

  • Nurul, A. A., Azlan, M., Ahmad Mohd Zain, M. R., Sebastian, A. A., Fan, Y. Z., & Fauzi, M. B. (2021). Mesenchymal Stem Cells: Current Concepts in the Management of Inflammation in Osteoarthritis. Biomedicines, 9(7), 785. Available from: https://doi.org/10.3390/biomedicines9070785
  • Kong, L., Zheng, L. Z., Qin, L., & Ho, K. (2017). Role of mesenchymal stem cells in osteoarthritis treatment. Journal of orthopaedic translation, 9, 89–103. Available in: https://doi.org/10.1016/j.jot.2017.03.006
  • Jorgensen C. (2013). Mesenchymal stem cells: uses in osteoarthritis. Joint bone spine, 80(6), 565–567. Available from: https://doi.org/10.1016/j.jbspin.2013.08.004
  • Gupta, P. K., Das, A. K., Chullikana, A., & Majumdar, A. S. (2012). Mesenchymal stem cells for cartilage repair in osteoarthritis. Stem cell research & therapy, 3(4), 25. Available from: https://doi.org/10.1186/scrt116
  • Kwon, D. G., Kim, M. K., Jeon, Y. S., Nam, Y. C., Park, J. S., & Ryu, D. J. (2022). State of the Art: The Immunomodulatory Role of MSCs for Osteoarthritis. International journal of molecular sciences, 23(3), 1618. Available from: https://doi.org/10.3390/ijms23031618
  • Jones, E. A., Crawford, A., English, A., Henshaw, K., Mundy, J., Corscadden, D., Chapman, T., Emery, P., Hatton, P., & McGonagle, D. (2008). Synovial fluid mesenchymal stem cells in health and early osteoarthritis: detection and functional evaluation at the single-cell level. Arthritis and rheumatism, 58(6), 1731–1740. Available from: https://doi.org/10.1002/art.23485
  • Scharstuhl, A., Schewe, B., Benz, K., Gaissmaier, C., Bühring, H. J., & Stoop, R. (2007). Chondrogenic potential of human adult mesenchymal stem cells is independent of age or osteoarthritis etiology. Stem cells (Dayton, Ohio), 25(12), 3244–3251. Available in: https://doi.org/10.1634/stemcells.2007-0300
  • Zhu, C., Wu, W., & Qu, X. (2021). Mesenchymal stem cells in osteoarthritis therapy: a review. American journal of translational research, 13(2), 448–461.
  • Harrell, C. R., Markovic, B. S., Fellabaum, C., Arsenijevic, A., & Volarevic, V. (2019). Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives. Biomedicine & pharmacotherapy. Biomedecine & pharmacotherapie, 109, 2318–2326. Available in: https://doi.org/10.1016/j.biopha.2018.11.099
  • Pers, Y. M., Ruiz, M., Noël, D., & Jorgensen, C. (2015). Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the art and perspectives. Osteoarthritis and cartilage, 23(11), 2027–2035. Available from: https://doi.org/10.1016/j.joca.2015.07.004
  • Taghiyar, L., Jahangir, S., Khozaei Ravari, M., Shamekhi, M. A., & Eslaminejad, M. B. (2021). Cartilage Repair by Mesenchymal Stem Cell-Derived Exosomes: Preclinical and Clinical Trial Update and Perspectives. Advances in experimental medicine and biology, 1326, 73–93. Available from: https://doi.org/10.1007/5584_2021_625
  • Wang, A. T., Feng, Y., Jia, H. H., Zhao, M., & Yu, H. (2019). Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review. World journal of stem cells, 11(4), 222–235. Available from: https://doi.org/10.4252/wjsc.v11.i4.222
  • Kim, G. B., & Shon, O. J. (2020). Current perspectives in stem cell therapies for osteoarthritis of the knee. Yeungnam University journal of medicine, 37(3), 149–158. Available from: https://doi.org/10.12701/yujm.2020.00157
  • Russo, E., Caprnda, M., Kruzliak, P., Conaldi, P. G., Borlongan, C. V., & La Rocca, G. (2022). Umbilical Cord Mesenchymal Stromal Cells for Cartilage Regeneration Applications. Stem cells international, 2022, 2454168. Available from: https://doi.org/10.1155/2022/2454168
  • Kangari, P., Talaei-Khozani, T., Razeghian-Jahromi, I., & Razmkhah, M. (2020). Mesenchymal stem cells: amazing remedies for bone and cartilage defects. Stem cell research & therapy, 11(1), 492. Available from: https://doi.org/10.1186/s13287-020-02001-1
  • Wang, A. T., Feng, Y., Jia, H. H., Zhao, M., & Yu, H. (2019). Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review. World journal of stem cells, 11(4), 222–235. Available from: https://doi.org/10.4252/wjsc.v11.i4.222
  • Wang, J., Zhou, L., Zhang, Y., Huang, L., & Shi, Q. (2020). Mesenchymal stem cells – a promising strategy for treating knee osteoarthritis. Bone & joint research, 9(10), 719–728. Available from: https://doi.org/10.1302/2046-3758.910.BJR-2020-0031.R3
  • Liang, H., Suo, H., Wang, Z., & Feng, W. (2020). Progress in the treatment of osteoarthritis with umbilical cord stem cells. Human cell, 33(3), 470–475. Available from: https://doi.org/10.1007/s13577-020-00377-z
  • Wang, H., Yan, X., Jiang, Y., Wang, Z., Li, Y., & Shao, Q. (2018). The human umbilical cord stem cells improve the viability of OA degenerated chondrocytes. Molecular medicine reports, 17(3), 4474–4482. Available from: https://doi.org/10.3892/mmr.2018.8413
  • Eder, C., Schmidt-Bleek, K., Geissler, S., Sass, F. A., Maleitzke, T., Pumberger, M., Perka, C., Duda, G. N., & Winkler, T. (2020). Mesenchymal stromal cell and bone marrow concentrate therapies for musculoskeletal indications: a concise review of current literature. Molecular biology reports, 47(6), 4789–4814. Availble from: https://doi.org/10.1007/s11033-020-05428-0
  • Li, K., Yan, G., Huang, H., Zheng, M., Ma, K., Cui, X., Lu, D., Zheng, L., Zhu, B., Cheng, J., & Zhao, J. (2022). Anti-inflammatory and immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages. Journal of nanobiotechnology, 20(1), 38. Available from: https://doi.org/10.1186/s12951-021-01236-1
  • Song, Y., Zhang, J., Xu, H., Lin, Z., Chang, H., Liu, W., & Kong, L. (2020). Mesenchymal stem cells in knee osteoarthritis treatment: A systematic review and meta-analysis. Journal of orthopaedic translation, 24, 121–130. Available from: https://doi.org/10.1016/j.jot.2020.03.015
  • Hwang, J. J., Rim, Y. A., Nam, Y., & Ju, J. H. (2021). Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Frontiers in immunology, 12, 631291. Available from: https://doi.org/10.3389/fimmu.2021.631291
  • Cheng, J. H., Wang, C. J., Chou, W. Y., Hsu, S. L., Chen, J. H., & Hsu, T. C. (2019). Comparison efficacy of ESWT and Wharton’s jelly mesenchymal stem cell in early osteoarthritis of rat knee. American journal of translational research, 11(2), 586–598.
  • Zhu, C., Wu, W., & Qu, X. (2021). Mesenchymal stem cells in osteoarthritis therapy: a review. American journal of translational research, 13(2), 448–461.
  • Han, Y., Li, X., Zhang, Y., Han, Y., Chang, F., & Ding, J. (2019). Mesenchymal Stem Cells for Regenerative Medicine. Cells, 8(8), 886. Available from: https://doi.org/10.3390/cells8080886
  • Navani A, Manchikanti L, Albers SL, Latchaw RE, Sanapati J, Kaye AD, Atluri S, Jordan S, Gupta A, Cedeno D, Vallejo A, Fellows B, Knezevic NN, Pappolla M, Diwan S, Trescot AM, Soin A, Kaye AM, Aydin SM, Calodney AK, Candido KD, Bakshi S, Benyamin RM, Vallejo R, Watanabe A, Beall D, Stitik TP, Foye PM, Helander EM, Hirsch JA. Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: American Society of Interventional Pain Physicians (ASIPP) Guidelines. Pain Physician. 2019 Jan;22(1S):S1-S74.
  • Leung, V. Y., Aladin, D. M., Lv, F., Tam, V., Sun, Y., Lau, R. Y., Hung, S. C., Ngan, A. H., Tang, B., Lim, C. T., Wu, E. X., Luk, K. D., Lu, W. W., Masuda, K., Chan, D., & Cheung, K. M. (2014). Mesenchymal stem cells reduce intervertebral disc fibrosis and facilitate repair. Stem cells (Dayton, Ohio), 32(8), 2164–2177. Available from: https://doi.org/10.1002/stem.1717
  • Lykov, A. P., Bondarenko, N. A., Poveshchenko, O. V., Kim, I. I., Surovtseva, M. A., Sadykova, J. B., Semin, P. A., Zavjalov, E. L., Krivoshapkin, A. L., & Konenkov, V. I. (2020). Treatment of Intervertebral Disc Degeneration in Wistar Rats with Mesenchymal Stem Cells. Bulletin of experimental biology and medicine, 168(4), 578–582. Available from: https://doi.org/10.1007/s10517-020-04756-2
  • Croft, A. S., Illien-Jünger, S., Grad, S., Guerrero, J., Wangler, S., & Gantenbein, B. (2021). The Application of Mesenchymal Stromal Cells and Their Homing Capabilities to Regenerate the Intervertebral Disc. International journal of molecular sciences, 22(7), 3519. Available from: https://doi.org/10.3390/ijms22073519
  • Wei, A., Shen, B., Williams, L., & Diwan, A. (2014). Mesenchymal stem cells: potential application in intervertebral disc regeneration. Translational pediatrics, 3(2), 71–90. Available from: https://doi.org/10.3978/j.issn.2224-4336.2014.03.05
  • Ekram, S., Khalid, S., Bashir, I., Salim, A., & Khan, I. (2021). Human umbilical cord-derived mesenchymal stem cells and their chondroprogenitor derivatives reduced pain and inflammation signaling and promote regeneration in a rat intervertebral disc degeneration model. Molecular and cellular biochemistry, 476(8), 3191–3205. Available from: https://doi.org/10.1007/s11010-021-04155-9
  • Sanapati J, Manchikanti L, Atluri S, Jordan S, Albers SL, Pappolla MA, Kaye AD, Candido KD, Pampati V, Hirsch JA. Do Regenerative Medicine Therapies Provide Long-Term Relief in Chronic Low Back Pain: A Systematic Review and Metaanalysis. Pain Physician. 2018 Nov;21(6):515-540.
  • Migliorini, F., Rath, B., Tingart, M., Baroncini, A., Quack, V., & Eschweiler, J. (2019). Autogenic mesenchymal stem cells for intervertebral disc regeneration. International orthopaedics, 43(4), 1027–1036. Available from: https://doi.org/10.1007/s00264-018-4218-y
  • Widjaja, G., Jalil, A. T., Budi, H. S., Abdelbasset, W. K., Efendi, S., Suksatan, W., Rita, R. S., Satria, A. P., Aravindhan, S., Saleh, M. M., Shalaby, M. N., & Yumashev, A. V. (2022). Mesenchymal stromal/stem cells and their exosomes application in the treatment of intervertebral disc disease: A promising frontier. International immunopharmacology, 105, 108537. Available from: https://doi.org/10.1016/j.intimp.2022.108537
  • Vadalà, G., Ambrosio, L., Russo, F., Papalia, R., & Denaro, V. (2019). Interaction between Mesenchymal Stem Cells and Intervertebral Disc Microenvironment: From Cell Therapy to Tissue Engineering. Stem cells international, 2019, 2376172. Available from: https://doi.org/10.1155/2019/2376172
  • Vadalà, G., Russo, F., Ambrosio, L., Papalia, R., & Denaro, V. (2016). Mesenchymal stem cells for intervertebral disc regeneration. Journal of biological regulators and homeostatic agents, 30(4 Suppl 1), 173–179.
  • Richardson, S. M., Kalamegam, G., Pushparaj, P. N., Matta, C., Memic, A., Khademhosseini, A., Mobasheri, R., Poletti, F. L., Hoyland, J. A., & Mobasheri, A. (2016). Mesenchymal stem cells in regenerative medicine: Focus on articular cartilage and intervertebral disc regeneration. Methods (San Diego, Calif.), 99, 69–80. Available from: https://doi.org/10.1016/j.ymeth.2015.09.015
  • Centeno, C., Markle, J., Dodson, E., Stemper, I., Williams, C. J., Hyzy, M., Ichim, T., & Freeman, M. (2017). Treatment of lumbar degenerative disc disease-associated radicular pain with culture-expanded autologous mesenchymal stem cells: a pilot study on safety and efficacy. Journal of translational medicine, 15(1), 197. Available from: https://doi.org/10.1186/s12967-017-1300-y
  • Noriega, D. C., Ardura, F., Hernández-Ramajo, R., Martín-Ferrero, M. Á., Sánchez-Lite, I., Toribio, B., Alberca, M., García, V., Moraleda, J. M., González-Vallinas, M., Sánchez, A., & García-Sancho, J. (2021). Treatment of Degenerative Disc Disease With Allogeneic Mesenchymal Stem Cells: Long-term Follow-up Results. Transplantation, 105(2), e25–e27. Available from: https://doi.org/10.1097/TP.0000000000003471
  • Liao, Z., Luo, R., Li, G., Song, Y., Zhan, S., Zhao, K., Hua, W., Zhang, Y., Wu, X., & Yang, C. (2019). Exosomes from mesenchymal stem cells modulate endoplasmic reticulum stress to protect against nucleus pulposus cell death and ameliorate intervertebral disc degeneration in vivo. Theranostics, 9(14), 4084–4100. Available from: https://doi.org/10.7150/thno.33638
  • Xia, C., Zeng, Z., Fang, B., Tao, M., Gu, C., Zheng, L., Wang, Y., Shi, Y., Fang, C., Mei, S., Chen, Q., Zhao, J., Lin, X., Fan, S., Jin, Y., & Chen, P. (2019). Mesenchymal stem cell-derived exosomes ameliorate intervertebral disc degeneration via anti-oxidant and antiinflammatory effects. Free radical biology & medicine, 143, 1–15. Available from: https://doi.org/10.1016/j.freeradbiomed.2019.07.026
  • Zhao, Y., Qin, Y., Wu, S., Huang, D., Hu, H., Zhang, X., & Hao, D. (2020). Mesenchymal stem cells regulate inflammatory milieu within degenerative nucleus pulposus cells via p38 MAPK pathway. Experimental and therapeutic medicine, 20(5), 22. Available from: https://doi.org/10.3892/etm.2020.9150
  • Zhao, Y. T., Qin, Y., Yang, J. S., Huang, D. G., Hu, H. M., Wang, X. D., Wu, S. F., & Hao, D. J. (2020). Wharton’s Jelly-derived mesenchymal stem cells suppress apoptosis of nucleus pulposus cells in intervertebral disc degeneration via Wnt pathway. European review for medical and pharmacological sciences, 24(19), 9807–9814. Available from: https://doi.org/10.26355/eurrev_202010_23190
  • Richardson, S. M., Hoyland, J. A., Mobasheri, R., Csaki, C., Shakibaei, M., & Mobasheri, A. (2010). Mesenchymal stem cells in regenerative medicine: opportunities and challenges for articular cartilage and intervertebral disc tissue engineering. Journal of cellular physiology, 222(1), 23–32. Available from: https://doi.org/10.1002/jcp.21915
  • Zeckser, J., Wolff, M., Tucker, J., & Goodwin, J. (2016). Multipotent Mesenchymal Stem Cell Treatment for Discogenic Low Back Pain and Disc Degeneration. Stem cells international, 2016, 3908389. Available from: https://doi.org/10.1155/2016/3908389
  • Yim, R. L., Lee, J. T., Bow, C. H., Meij, B., Leung, V., Cheung, K. M., Vavken, P., & Samartzis, D. (2014). A systematic review of the safety and efficacy of mesenchymal stem cells for disc degeneration: insights and future directions for regenerative therapeutics. Stem cells and development, 23(21), 2553–2567. Available from: https://doi.org/10.1089/scd.2014.0203

Neurodegenerative and Neurological Conditions

  • Földes, A., Kádár, K., Kerémi, B., Zsembery, Á., Gyires, K., S Zádori, Z., & Varga, G. (2016). Mesenchymal Stem Cells of Dental Origin-Their Potential for Antiinflammatory and Regenerative Actions in Brain and Gut Damage. Current neuropharmacology, 14(8), 914–934. https://doi.org/10.2174/1570159×14666160121115210
  • Liu S, Zhang H, Wang H, Huang J, Yang Y, Li G, Yu K, Yang L. A Comparative Study of Different Stem Cell Transplantation for Spinal Cord Injury: A Systematic Review and Network Meta-Analysis. World Neurosurg. 2021 Dec 22:S1878-8750(21)01879-9.
  • Muthu S, Jeyaraman M, Gulati A, Arora A. Current evidence on mesenchymal stem cell therapy for traumatic spinal cord injury: systematic review and meta-analysis. Cytotherapy. 2021 Mar;23(3):186-197.
  • Albu S, Kumru H, Coll R, Vives J, Vallés M, Benito-Penalva J, Rodríguez L, Codinach M, Hernández J, Navarro X, Vidal J. Clinical effects of intrathecal administration of expanded Wharton jelly mesenchymal stromal cells in patients with chronic complete spinal cord injury: a randomized controlled study. Cytotherapy. 2021 Feb;23(2):146-156
  • Khan, S., Mafi, P., Mafi, R., & Khan, W. (2018). A Systematic Review of Mesenchymal Stem Cells in Spinal Cord Injury, Intervertebral Disc Repair and Spinal Fusion. Current stem cell research & therapy, 13(4), 316–323. Available from: https://doi.org/10.2174/1574888X11666170907120030
  • Liau, L. L., Looi, Q. H., Chia, W. C., Subramaniam, T., Ng, M. H., & Law, J. X. (2020). Treatment of spinal cord injury with mesenchymal stem cells. Cell & bioscience, 10, 112. Available from: https://doi.org/10.1186/s13578-020-00475-3
  • Boncoraglio GB, Ranieri M, Bersano A, Parati EA, Del Giovane C. Stem cell transplantation for ischemic stroke. Cochrane Database Syst Rev. 2019 May 5;5(5):CD007231. Available from: https://doi.org/10.1002/14651858.CD007231.pub3
  • Hess DC, Wechsler LR, Clark WM, Savitz SI, Ford GA, Chiu D, Yavagal DR, Uchino K, Liebeskind DS, Auchus AP, Sen S, Sila CA, Vest JD, Mays RW. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017 May;16(5):360-368. Available from: https://doi.org/10.1016/S1474-4422(17)30046-7
  • Laskowitz DT, Bennett ER, Durham RJ, Volpi JJ, Wiese JR, Frankel M, Shpall E, Wilson JM, Troy J, Kurtzberg J. Allogeneic Umbilical Cord Blood Infusion for Adults with Ischemic Stroke: Clinical Outcomes from a Phase I Safety Study. Stem Cells Transl Med. 2018 Jul;7(7):521-529. Available from: https://doi.org/10.1002/sctm.18-0008
  • Fang J, Guo Y, Tan S, Li Z, Xie H, Chen P, Wang K, He Z, He P, Ke Y, Jiang X, Chen Z. Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study. Stem Cells Transl Med. 2019 Jan;8(1):14-21. Available from: https://doi.org/10.1002/sctm.18-0012
  • Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005 Jun;57(6):874-82. Available from: https://doi.org/10.1002/ana.20501
  • Jaillard A, Hommel M, Moisan A, Zeffiro TA, Favre-Wiki IM, Barbieux-Guillot M, Vadot W, Marcel S, Lamalle L, Grand S, Detante O; (for the ISIS-HERMES Study Group). Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial. Transl Stroke Res. 2020 Oct;11(5):910-923. Available from: https://doi.org/10.1007/s12975-020-00787-z
  • Jiang Y, Zhu W, Zhu J, Wu L, Xu G, Liu X. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013;22(12):2291-8. Available from: https://doi.org/10.3727/096368912X658818
  • Lee JS, Hong JM, Moon GJ, Lee PH, Ahn YH, Bang OY; STARTING collaborators. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010 Jun;28(6):1099-106.
  • Bhasin A, Srivastava MV, Kumaran SS, Mohanty S, Bhatia R, Bose S, Gaikwad S, Garg A, Airan B. Autologous mesenchymal stem cells in chronic stroke. Cerebrovasc Dis Extra. 2011 Jan-Dec;1(1):93-104. Available from: https://doi.org/10.1159/000333381
  • Bhasin A, Kumaran SS, Bhatia R, Mohanty S, Srivastava MVP. Safety and Feasibility of Autologous Mesenchymal Stem Cell Transplantation in Chronic Stroke in Indian patients. A four-year follow up. J Stem Cells Regen Med. 2017 May 30;13(1):14-19. Available from: https://doi.org/10.46582/jsrm.1301003
  • Levy ML, Crawford JR, Dib N, Verkh L, Tankovich N, Cramer SC. Phase I/II Study of Safety and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Chronic Stroke. Stroke. 2019 Oct;50(10):2835-2841. Available from: https://doi.org/10.1161/STROKEAHA.119.026318
  • Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Coburn ML, Billigen JB, Kim AS, Johnson JN, Bates D, King B, Case C, McGrogan M, Yankee EW, Schwartz NE. Clinical Outcomes of Transplanted Modified Bone Marrow-Derived Mesenchymal Stem Cells in Stroke: A Phase 1/2a Study. Stroke. 2016 Jul;47(7):1817-24. Available from: https://doi.org/10.1161/STROKEAHA.116.012995
  • Steinberg GK, Kondziolka D, Wechsler LR, Lunsford LD, Kim AS, Johnson JN, Bates D, Poggio G, Case C, McGrogan M, Yankee EW, Schwartz NE. Two-year safety and clinical outcomes in chronic ischemic stroke patients after implantation of modified bone marrow-derived mesenchymal stem cells (SB623): a phase 1/2a study. J Neurosurg. 2018 Nov 23:1-11. Available from: https://doi.org/10.3171/2018.5.JNS173147
  • Chung JW, Chang WH, Bang OY, Moon GJ, Kim SJ, Kim SK, Lee JS, Sohn SI, Kim YH; STARTING-2 Collaborators. Efficacy and Safety of Intravenous Mesenchymal Stem Cells for Ischemic Stroke. Neurology. 2021 Feb 16;96(7):e1012-e1023. Available from: https://doi.org/10.1212/WNL.0000000000011440
  • Lee J, Chang WH, Chung JW, Kim SJ, Kim SK, Lee JS, Sohn SI, Kim YH, Bang OY; STARTING-2 Collaborators. Efficacy of Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic Stroke: A Neuroimaging Study. Stroke. 2022 Jan;53(1):20-28. Available from: https://doi.org/10.1161/STROKEAHA
  • Meng, M., Liu, Y., Wang, W., Wei, C., Liu, F., Du, Z., Xie, Y., Tang, W., Hou, Z., & Li, Q. (2018). Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis. American journal of translational research, 10(1), 212–223. Available from: Umbilical cord mesenchymal stem cell transplantation in the treatment of multiple sclerosis (nih.gov)
  • He Jialin, Huang Yan, Liu Jianyang, Lan Ziwei, Tang Xiangqi, Hu Zhiping. (2021) The Efficacy of Mesenchymal Stem Cell Therapies in Rodent Models of Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis. Frontiers in Immunology. 12; 2021 Available from: https://doi.org10.3389/fimmu.2021.711362
  • Mansoor SR, Zabihi E, Ghasemi-Kasman M. The potential use of mesenchymal stem cells for the treatment of multiple sclerosis. Life Sci. 2019 Oct 15;235:116830. Available from: https://doi.org/10.1016/j.lfs.2019.116830
  • Li, Jin-Feng, et al. “The Potential of Human Umbilical Cord-Derived Mesenchymal Stem Cells as a Novel Cellular Therapy for Multiple Sclerosis.” Cell Transplantation, Jan. 2014, pp. 113–122, Available from: https://doi.org/10.3727/096368914X685005
  • Gugliandolo, A., Bramanti, P., & Mazzon, E. (2020). Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies. International journal of molecular sciences, 21(22), 8662. Available from: https://doi.org/10.3390/ijms21228662
  • Xiao J, Yang R, Biswas S, Qin X, Zhang M, Deng W. Mesenchymal Stem Cells and Induced Pluripotent Stem Cells as Therapies for Multiple Sclerosis. International Journal of Molecular Sciences. 2015; 16(5):9283-9302. Available from: https://doi.org/10.3390/ijms16059283
  • Riordan, N. H., Morales, I., Fernández, G., Allen, N., Fearnot, N. E., Leckrone, M. E., Markovich, D. J., Mansfield, D., Avila, D., Patel, A. N., Kesari, S., & Paz Rodriguez, J. (2018). Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. Journal of translational medicine, 16(1), 57. Available from: https://doi.org/10.1186/s12967-018-1433-7
  • Jafarzadeh Bejargafshe, M., Hedayati, M., Zahabiasli, S., Tahmasbpour, E., Rahmanzadeh, S., & Nejad-Moghaddam, A. (2019). Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis. Stem cell investigation, 6, 44. Available from: https://doi.org/10.21037/sci.2019.10.06
  • Lu, Z., Zhu, L., Liu, Z., Wu, J., Xu, Y., & Zhang, C. J. (2020). IV/IT hUC-MSCs Infusion in RRMS and NMO: A 10-Year Follow-Up Study. Frontiers in neurology, 11, 967. Available from: https://doi.org/10.3389/fneur.2020.00967
  • Connick, P., Kolappan, M., Crawley, C., Webber, D. J., Patani, R., Michell, A. W., Du, M. Q., Luan, S. L., Altmann, D. R., Thompson, A. J., Compston, A., Scott, M. A., Miller, D. H., & Chandran, S. (2012). Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. The Lancet. Neurology, 11(2), 150–156. Available from: https://doi.org/10.1016/S1474-4422(11)70305-2
  • Sun, J. M., Dawson, G., Franz, L., Howard, J., McLaughlin, C., Kistler, B., Waters-Pick, B., Meadows, N., Troy, J., & Kurtzberg, J. (2020). Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. Stem cells translational medicine, 9(10), 1137–1146. Available from: https://doi.org/10.1002/sctm.19-0434
  • Siniscalco, D., Bradstreet, J. J., Sych, N., & Antonucci, N. (2013). Perspectives on the use of stem cells for autism treatment. Stem cells international, 2013, 262438. Available from: https://doi.org/10.1155/2013/262438
  • Lv, Y. T., Zhang, Y., Liu, M., Qiuwaxi, J. N., Ashwood, P., Cho, S. C., Huan, Y., Ge, R. C., Chen, X. W., Wang, Z. J., Kim, B. J., & Hu, X. (2013). Transplantation of human cord blood mononuclear cells and umbilical cord-derived mesenchymal stem cells in autism. Journal of translational medicine, 11, 196. Available from: https://doi.org/10.1186/1479-5876-11-196
  • Simberlund, J., Ferretti, C. J., & Hollander, E. (2015). Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 16(6), 368–375. Available from: https://doi.org/10.3109/15622975.2015.1067372
  • Freitas, B. C., Trujillo, C. A., Carromeu, C., Yusupova, M., Herai, R. H., & Muotri, A. R. (2014). Stem cells and modeling of autism spectrum disorders. Experimental neurology, 260, 33–43. Available from: https://doi.org/10.1016/j.expneurol.2012.09.017
  • Perets, N., Segal-Gavish, H., Gothelf, Y., Barzilay, R., Barhum, Y., Abramov, N., Hertz, S., Morozov, D., London, M., & Offen, D. (2017). Long term beneficial effect of neurotrophic factors-secreting mesenchymal stem cells transplantation in the BTBR mouse model of autism. Behavioural brain research, 331, 254–260. Available from: https://doi.org/10.1016/j.bbr.2017.03.047
  • Chez, M., Lepage, C., Parise, C., Dang-Chu, A., Hankins, A., & Carroll, M. (2018). Safety and Observations from a Placebo-Controlled, Crossover Study to Assess Use of Autologous Umbilical Cord Blood Stem Cells to Improve Symptoms in Children with Autism. Stem cells translational medicine, 7(4), 333–341. Available from: https://doi.org/10.1002/sctm.17-0042
  • Siniscalco, D., Bradstreet, J. J., Sych, N., & Antonucci, N. (2014). Mesenchymal stem cells in treating autism: Novel insights. World journal of stem cells, 6(2), 173–178. Available from: https://doi.org/10.4252/wjsc.v6.i2.173
  • Liang, Y., Duan, L., Xu, X., Li, X., Liu, M., Chen, H., Lu, J., & Xia, J. (2020). Mesenchymal Stem Cell-Derived Exosomes for Treatment of Autism Spectrum Disorder. ACS applied bio materials, 3(9), 6384–6393. Available from: https://doi.org/10.1021/acsabm.0c00831
  • Liu, Q., Chen, M. X., Sun, L., Wallis, C. U., Zhou, J. S., Ao, L. J., Li, Q., & Sham, P. C. (2019). Rational use of mesenchymal stem cells in the treatment of autism spectrum disorders. World journal of stem cells, 11(2), 55–72. Available from: https://doi.org/10.4252/wjsc.v11.i2.55
  • Gesundheit, B., Ashwood, P., Keating, A., Naor, D., Melamed, M., & Rosenzweig, J. P. (2015). Therapeutic properties of mesenchymal stem cells for autism spectrum disorders. Medical hypotheses, 84(3), 169–177. Available from: https://doi.org/10.1016/j.mehy.2014.12.016

Urological Conditions

  • Yao C, Zhang X, Yu Z, et al., Effects of Stem Cell Therapy on Diabetic Mellitus Erectile Dysfunction: A Systematic Review and Meta-analysis. J Sex Med 2022;19:21–36.
  • Al Demour S, Adwan S, Jafar H, Rahmeh R, Alhawari H, Awidi A. Safety and Efficacy of 2 Intracavernous Injections of Allogeneic Wharton’s Jelly-Derived Mesenchymal Stem Cells in Diabetic Patients with Erectile Dysfunction: Phase 1/2 Clinical Trial. Urol Int. 2021;105(11-12):935- 943.
  • Al Demour S, Jafar H, Adwan S, AlSharif A, Alhawari H, Alrabadi A, Zayed A, Jaradat A, Awidi A. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. Urol Int. 2018;101(3):358-365.
  • You D, Jang MJ, Song G, Shin HC, Suh N, Kim YM, Ahn TY, Kim CS. Safety of autologous bone marrow-derived mesenchymal stem cells in erectile dysfunction: an open-label phase 1 clinical trial. Cytotherapy. 2021 Oct;23(10):931-938

Endocrine Conditions

  • Solis, M. A., Moreno Velásquez, I., Correa, R., & Huang, L. (2019). Stem cells as a potential therapy for diabetes mellitus: a call-to-action in Latin America. Diabetology & metabolic syndrome, 11, 20. Available from: https://doi.org/10.1186/s13098-019-0415-0
  • Scuteri, A., & Monfrini, M. (2018). Mesenchymal Stem Cells as New Therapeutic Approach for Diabetes and Pancreatic Disorders. International journal of molecular sciences, 19(9), 2783. Available from: https://doi.org/10.3390/ijms19092783
  • He, J., Kong, D., Yang, Z., Guo, R., Amponsah, A. E., Feng, B., Zhang, X., Zhang, W., Liu, A., Ma, J., O’Brien, T., & Cui, H. (2021). Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. PloS one, 16(3), e0247662. Available from: https://doi.org/10.1371/journal.pone.0247662
  • de Klerk, E., & Hebrok, M. (2021). Stem Cell-Based Clinical Trials for Diabetes Mellitus. Frontiers in endocrinology, 12, 631463. Available from: https://doi.org/10.3389/fendo.2021.631463
  • Moreira, A., Kahlenberg, S., & Hornsby, P. (2017). Therapeutic potential of mesenchymal stem cells for diabetes. Journal of molecular endocrinology, 59(3), R109–R120. Available from: https://doi.org/10.1530/JME-17-0117
  • Kamal, M. M., & Kassem, D. H. (2020). Therapeutic Potential of Wharton’s Jelly Mesenchymal Stem Cells for Diabetes: Achievements and Challenges. Frontiers in cell and developmental biology, 8, 16. Available from: https://doi.org/10.3389/fcell.2020.00016
  • Kakkar, A., Sorout, A., Tiwari, M., Shrivastava, P., Meena, P., Saraswat, S. K., Srivastava, S., Datt, R., & Pandey, S. (2018). Current Status of Stem Cell Treatment for Type I Diabetes Mellitus. Tissue engineering and regenerative medicine, 15(6), 699–709. Available from: https://doi.org/10.1007/s13770-018-0143-9
  • Vija, D. Farge, J.-F. Gautier, P. Vexiau, C. Dumitrache, A. Bourgarit, F. Verrecchia, J. Larghero, Mesenchymal stem cells: Stem cell therapy perspectives for type 1 diabetes, Diabetes & Metabolism, Volume 35, Issue 2, 2009: 85-93, Available from: https://doi.org/10.1016/j.diabet.2008.10.003.
  • Rekittke, N. E., Ang, M., Rawat, D., Khatri, R., & Linn, T. (2016). Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem Cells. Stem cells international, 2016, 3764681. Available from: https://doi.org/10.1155/2016/3764681
  • Takahashi, H., Sakata, N., Yoshimatsu, G., Hasegawa, S., & Kodama, S. (2019). Regenerative and Transplantation Medicine: Cellular Therapy Using Adipose Tissue-Derived Mesenchymal Stromal Cells for Type 1 Diabetes Mellitus. Journal of clinical medicine, 8(2), 249. Available from: https://doi.org/10.3390/jcm8020249
  • Carlsson PO, Schwarcz E, Korsgren O, Le Blanc K. Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells. Diabetes. 2015;64(2): 587–592. Epub 2014/09/09. Available from: https://doi.org/10.2337/db14-0656
  • Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Endocr J. 2013;60(3):347-57. Available from: https://doi.org/10.1507/endocrj.ej12-0343
  • Qi, Y., Ma, J., Li, S., & Liu, W. (2019). Applicability of adipose-derived mesenchymal stem cells in treatment of patients with type 2 diabetes. Stem cell research & therapy, 10(1), 274. Available from: https://doi.org/10.1186/s13287-019-1362-2
  • Bhansali S, Dutta P, Kumar V, Yadav MK, Jain A, Mudaliar S, et al.. Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study. Stem Cells Dev. 2017;26(7): 471–481. Available from:https://doi.org/10.1089/scd.2016.0275
  • Chen P, Huang Q, Xu XJ, Shao ZL, Huang LH, Yang XZ, Guo W, Li CM, Chen C. [The effect of liraglutide in combination with human umbilical cord mesenchymal stem cells treatment on glucose metabolism and β cell function in type 2 diabetes mellitus]. Zhonghua Nei Ke Za Zhi. 2016 May 1;55(5):349-54. Available from:  https://doi.org/10.3760/cma.j.issn.0578-1426.2016.05.004
  • Hu J, Wang Y, Gong H, Yu C, Guo C, Wang F, Yan S, Xu H. Long term effect and safety of Wharton’s jelly-derived mesenchymal stem cells on type 2 diabetes. Exp Ther Med. 2016 Sep;12(3):1857-1866. Available form: https://doi.org/10.3892/etm.2016.3544
  • Zhang, X., Xu, L., & Zhou, Y. H. (2016). Safety and efficacy of allogeneic amniotic mesenchymal stem cells transplantation in the treatment of newly-onset type 1 diabetes mellitus. Shandong Medical Journal, 56(29), 44-46.
  • Zhou, X. X. W., Chen, L. Z. Y., & Wu, J. C. J. (2013). Clinical study of autologous bone marrow mesenchymal stem cells transplantation in the treatment of type 2 diabetes mellitus. Contemporary Medicine, 19(17), 20-21.
  • Li, Y., Wang, F., Liang, H., Tang, D., Huang, M., Zhao, J., Yang, X., Liu, Y., Shu, L., Wang, J., He, Z., & Liu, Y. (2021). Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus: a meta-analysis. Stem cell research & therapy, 12(1), 273. https://doi.org/10.1186/s13287-021-02342-5

Chronic Gastrointestinal Inflammatory Conditions

  • Mishra, R., Dhawan, P., Srivastava, A. S., & Singh, A. B. (2020). Inflammatory bowel disease: Therapeutic limitations and prospective of the stem cell therapy. World journal of stem cells, 12(10), 1050–1066. Available from: https://doi.org/10.4252/wjsc.v12.i10.1050
  • Ko, J. Z., Johnson, S., & Dave, M. (2021). Efficacy and Safety of Mesenchymal Stem/Stromal Cell Therapy for Inflammatory Bowel Diseases: An Up-to-Date Systematic Review. Biomolecules, 11(1), 82. Available from: https://doi.org/10.3390/biom11010082
  • Algeri, M., Conforti, A., Pitisci, A., Starc, N., Tomao, L., Bernardo, M. E., & Locatelli, F. (2015). Mesenchymal stromal cells and chronic inflammatory bowel disease. Immunology letters, 168(2), 191–200. Available from: https://doi.org/10.1016/j.imlet.2015.06.018
  • Xu, J., Wang, X., Chen, J., Chen, S., Li, Z., Liu, H., Bai, Y., & Zhi, F. (2020). Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice. Theranostics, 10(26), 12204–12222. Available from: https://doi.org/10.7150/thno.47683
  • Carvello, M., Lightner, A., Yamamoto, T., Kotze, P. G., & Spinelli, A. (2019). Mesenchymal Stem Cells for Perianal Crohn’s Disease. Cells, 8(7), 764. Available from: https://doi.org/10.3390/cells8070764
  • Zhang, J., Lv, S., Liu, X., Song, B., & Shi, L. (2018). Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn’s Disease: A Randomized Controlled Clinical Trial. Gut and liver, 12(1), 73–78. Available from: https://doi.org/10.5009/gnl17035
  • Cao, Y., Su, Q., Zhang, B. et al. Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther 12, 32 (2021). Available from: https://doi.org/10.1186/s13287-020-02095-7
  • Ciccocioppo, R., Cangemi, G. C., Kruzliak, P., Gallia, A., Betti, E., Badulli, C., Martinetti, M., Cervio, M., Pecci, A., Bozzi, V., Dionigi, P., Visai, L., Gurrado, A., Alvisi, C., Picone, C., Monti, M., Bernardo, M. E., Gobbi, P., & Corazza, G. R. (2015). Ex vivo immunosuppressive effects of mesenchymal stem cells on Crohn’s disease mucosal T cells are largely dependent on indoleamine 2,3-dioxygenase activity and cell-cell contact. Stem cell research & therapy, 6(1), 137. Available from: https://doi.org/10.1186/s13287-015-0122-1
  • Bernardi, L., Santos, C., Pinheiro, V., Oliveira, R. J., & Antoniolli-Silva, A. (2019). Transplantation Of Adipose-derived Mesenchymal Stem Cells In Refractory Crohn’s Disease: Systematic Review. Arquivos brasileiros de cirurgia digestiva : ABCD = Brazilian archives of digestive surgery, 32(4), e1465. Available from: https://doi.org/10.1590/0102-672020190001e1465
  • Gallo, G., Tiesi, V., Fulginiti, S., De Paola, G., Vescio, G., & Sammarco, G. (2020). Mesenchymal Stromal Cell Therapy in the Management of Perianal Fistulas in Crohn’s Disease: An Up-To-Date Review. Medicina (Kaunas, Lithuania), 56(11), 563. Available from: https://doi.org/10.3390/medicina56110563
  • Grim, C., Noble, R., Uribe, G., Khanipov, K., Johnson, P., Koltun, W. A., Watts, T., Fofanov, Y., Yochum, G. S., Powell, D. W., Beswick, E. J., & Pinchuk, I. V. (2021). Impairment of Tissue-Resident Mesenchymal Stem Cells in Chronic Ulcerative Colitis and Crohn’s Disease. Journal of Crohn’s & colitis, 15(8), 1362–1375. Available from: https://doi.org/10.1093/ecco-jcc/jjab001
  • Włodarczyk, M., Czerwińska, K., Włodarczyk, J., Fichna, J., Dziki, A., & Dziki, Ł. (2021). Current Overview on the Use of Mesenchymal Stem Cells for Perianal Fistula Treatment in Patients with Crohn’s Disease. Life (Basel, Switzerland), 11(11), 1133. Available from: https://doi.org/10.3390/life11111133
  • Dailey, F. E., Turse, E. P., Naseer, M., Bragg, J. D., & Tahan, V. (2018). Review of stem cells as promising therapy for perianal disease in inflammatory bowel disease. World journal of transplantation, 8(4), 97–101. Available from: https://doi.org/10.5500/wjt.v8.i4.97
  • Martínez-Montiel, M., Gómez-Gómez, G. J., & Flores, A. I. (2014). Therapy with stem cells in inflammatory bowel disease. World journal of gastroenterology, 20(5), 1211–1227. Available from: https://doi.org/10.3748/wjg.v20.i5.1211
  • Grégoire, C., Lechanteur, C., Briquet, A., Baudoux, É., Baron, F., Louis, E., & Beguin, Y. (2017). Review article: mesenchymal stromal cell therapy for inflammatory bowel diseases. Alimentary pharmacology & therapeutics, 45(2), 205–221. Available from: https://doi.org/10.1111/apt.13864
  • Shi, X., Chen, Q., & Wang, F. (2019). Mesenchymal stem cells for the treatment of ulcerative colitis: a systematic review and meta-analysis of experimental and clinical studies. Stem cell research & therapy, 10(1), 266. Available from: https://doi.org/10.1186/s13287-019-1336-4
  • Hosseini-Asl, S. K., Mehrabani, D., & Karimi-Busheri, F. (2020). Therapeutic Effect of Mesenchymal Stem Cells in Ulcerative Colitis: A Review on Achievements and Challenges. Journal of clinical medicine, 9(12), 3922. Available from: https://doi.org/10.3390/jcm9123922
  • Huldani, H., Margiana, R., Ahmad, F., Opulencia, M., Ansari, M. J., Bokov, D. O., Abdullaeva, N. N., & Siahmansouri, H. (2022). Immunotherapy of inflammatory bowel disease (IBD) through mesenchymal stem cells. International immunopharmacology, 107, 108698. Advance online publication. Available from: https://doi.org/10.1016/j.intimp.2022.108698
  • Hu, J., Zhao, G., Zhang, L., Qiao, C., Di, A., Gao, H., & Xu, H. (2016). Safety and therapeutic effect of mesenchymal stem cell infusion on moderate to severe ulcerative colitis. Experimental and therapeutic medicine, 12(5), 2983–2989. Available from: https://doi.org/10.3892/etm.2016.3724
  • Choi, Y. J., Koo, J. B., Kim, H. Y., Seo, J. W., Lee, E. J., Kim, W. R., Cho, J. Y., Hahm, K. B., Hong, S. P., Kim, D. H., & Yoo, J. H. (2019). Umbilical cord/placenta-derived mesenchymal stem cells inhibit fibrogenic activation in human intestinal myofibroblasts via inhibition of myocardin-related transcription factor A. Stem cell research & therapy, 10(1), 291. Available from: https://doi.org/10.1186/s13287-019-1385-8
  • Lazebnik, L. B., Kniazev, O. V., Konopliannikov, A. G., Parfenov, A. I., Ruchkina, I. N., Mikhaĭlova, Z. F., Tsaregorodtseva, T. M., Khomeriki, S. G., Rogozina, V. A., Gudkova, R. B., Shcherbakov, P. L., & Konopliannikova, O. A. (2010). Eksperimental’naia i klinicheskaia gastroenterologiia. Experimental & clinical gastroenterology, (11), 3–15.
  • Knyazev, O. V., Parfenov, A. I., Konoplyannikov, A. G., & Boldyreva, O. N. (2016). Terapevticheskii arkhiv, 88(2), 44–48. Available from: https://doi.org/10.17116/terarkh201688244-48

Autoimmune Conditions

  • Markov, A., Thangavelu, L., Aravindhan, S., Zekiy, A. O., Jarahian, M., Chartrand, M. S., Pathak, Y., Marofi, F., Shamlou, S., & Hassanzadeh, A. (2021). Mesenchymal stem/stromal cells as a valuable source for the treatment of immune-mediated disorders. Stem cell research & therapy, 12(1), 192. Available from: https://doi.org/10.1186/s13287-021-02265-1
  • Jiang, W., & Xu, J. (2020). Immune modulation by mesenchymal stem cells. Cell proliferation, 53(1), e12712. Available from: https://doi.org/10.1111/cpr.12712
  • Lv, X., Wang, L., Zou, X., & Huang, S. (2021). Umbilical Cord Mesenchymal Stem Cell Therapy for Regenerative Treatment of Rheumatoid Arthritis: Opportunities and Challenges. Drug design, development and therapy, 15, 3927–3936. Available from: https://doi.org/10.2147/DDDT.S323107
  • Zhang, Q., Li, Q., Zhu, J., Guo, H., Zhai, Q., Li, B., Jin, Y., He, X., & Jin, F. (2019). Comparison of therapeutic effects of different mesenchymal stem cells on rheumatoid arthritis in mice. PeerJ, 7, e7023. Available from: https://doi.org/10.7717/peerj.7023
  • Sonomoto, K., Yamaoka, K., & Tanaka, Y. (2014). Journal of UOEH, 36(2), 141–146. Available from: https://doi.org/10.7888/juoeh.36.141
  • Tanaka, Y., Sonomoto, K., Kondo, M., Oshita, K., Zhang, X. M., Fukuyo, S., & Yamaoka, K. (2015). Nihon Rinsho Men’eki Gakkai kaishi. Japanese journal of clinical immunology, 38(2), 86–92. Available from: https://doi.org/10.2177/jsci.38.86
  • Oshita, K., Yamaoka, K., & Tanaka, Y. (2013). Journal of UOEH, 35(1), 33–37. Available from: https://doi.org/10.7888/juoeh.35.33
  • Tanaka Y. (2015). Human mesenchymal stem cells as a tool for joint repair in rheumatoid arthritis. Clinical and experimental rheumatology, 33(4 Suppl 92), S58–S62.
  • Wang, L., Wang, L., Cong, X., Liu, G., Zhou, J., Bai, B., Li, Y., Bai, W., Li, M., Ji, H., Zhu, D., Wu, M., & Liu, Y. (2013). Human umbilical cord mesenchymal stem cell therapy for patients with active rheumatoid arthritis: safety and efficacy. Stem cells and development, 22(24), 3192–3202. Available from: https://doi.org/10.1089/scd.2013.0023
  • El-Jawhari, J. J., El-Sherbiny, Y. M., Jones, E. A., & McGonagle, D. (2014). Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM: monthly journal of the Association of Physicians, 107(7), 505–514. Available from: https://doi.org/10.1093/qjmed/hcu033
  • Ansboro, S., Roelofs, A. J., & De Bari, C. (2017). Mesenchymal stem cells for the management of rheumatoid arthritis: immune modulation, repair or both?. Current opinion in rheumatology, 29(2), 201–207. Availble from: https://doi.org/10.1097/BOR.0000000000000370
  • Lopez-Santalla, M., Fernandez-Perez, R., & Garin, M. I. (2020). Mesenchymal Stem/Stromal Cells for Rheumatoid Arthritis Treatment: An Update on Clinical Applications. Cells, 9(8), 1852. Available from: https://doi.org/10.3390/cells9081852
  • Zhu, H., Jiang, X. X., Wu, Y., Liu, Y. L., Li, X. S., Zhang, Y., & Mao, N. (2009). Zhongguo shi yan xue ye xue za zhi, 17(4), 977–980.
  • Hwang, J. J., Rim, Y. A., Nam, Y., & Ju, J. H. (2021). Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Frontiers in immunology, 12, 631291. Available from: https://doi.org/10.3389/fimmu.2021.631291
  • Luque-Campos, N., Contreras-López, R. A., Jose Paredes-Martínez, M., Torres, M. J., Bahraoui, S., Wei, M., Espinoza, F., Djouad, F., Elizondo-Vega, R. J., & Luz-Crawford, P. (2019). Mesenchymal Stem Cells Improve Rheumatoid Arthritis Progression by Controlling Memory T Cell Response. Frontiers in immunology, 10, 798. Available from: https://doi.org/10.3389/fimmu.2019.00798
  • Keerthi, N., Chimutengwende-Gordon, M., Sanghani, A., & Khan, W. (2013). The potential of stem cell therapy for osteoarthritis and rheumatoid arthritis. Current stem cell research & therapy, 8(6), 444–450. Available from: https://doi.org/10.2174/1574888×1130800062
  • El-Jawhari, J. J., El-Sherbiny, Y. M., Jones, E. A., & McGonagle, D. (2014). Mesenchymal stem cells, autoimmunity and rheumatoid arthritis. QJM: monthly journal of the Association of Physicians, 107(7), 505–514. Available from: https://doi.org/10.1093/qjmed/hcu033
  • Liu, H., Li, R., Liu, T., Yang, L., Yin, G., & Xie, Q. (2020). Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis. Frontiers in immunology, 11, 1912. Available from: https://doi.org/10.3389/fimmu.2020.01912
  • Hwang, J. J., Rim, Y. A., Nam, Y., & Ju, J. H. (2021). Recent Developments in Clinical Applications of Mesenchymal Stem Cells in the Treatment of Rheumatoid Arthritis and Osteoarthritis. Frontiers in immunology, 12, 631291. Available from: https://doi.org/10.3389/fimmu.2021.631291
  • Wang, L., Huang, S., Li, S., Li, M., Shi, J., Bai, W., Wang, Q., Zheng, L., & Liu, Y. (2019). Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cell Therapy for Rheumatoid Arthritis Patients: A Prospective Phase I/II Study. Drug design, development and therapy, 13, 4331–4340. Avalailable from: https://doi.org/10.2147/DDDT.S225613
  • Zhang, Z., Ding, Y., Li, W., Song, B., & Yang, R. (2013). Interleukin-17A- or tumor necrosis factor α-mediated increase in proliferation of T cells cocultured with synovium-derived mesenchymal stem cells in rheumatoid arthritis. Arthritis research & therapy, 15(5), R169. Available from: https://doi.org/10.1186/ar4355
  • Sarsenova, M., Issabekova, A., Abisheva, S., Rutskaya-Moroshan, K., Ogay, V., & Saparov, A. (2021). Mesenchymal Stem Cell-Based Therapy for Rheumatoid Arthritis. International journal of molecular sciences, 22(21), 11592. Available from: https://doi.org/10.3390/ijms222111592
  • Serakinci, N., & Savtekin, G. (2017). Modeling Mesenchymal Stem Cells in TMJ Rheumatoid Arthritis and Osteoarthritis Therapy. Critical reviews in eukaryotic gene expression, 27(3), 205–210. Available from: https://doi.org/10.1615/CritRevEukaryotGeneExpr.2017019380

Dermatological Conditions

  • Chen, Y., Yu, Q., Hu, Y., & Shi, Y. (2019). Current Research and Use of Mesenchymal Stem Cells in the Therapy of Autoimmune Diseases. Current stem cell research & therapy, 14(7), 579–582. Available from: https://doi.org/10.2174/1574888X14666190429141421
  • Paganelli, A., Kaleci, S., Benassi, L., Pellacani, G., & Magnoni, C. (2020). Mesenchymal stem cells and psoriasis: State of the art and future perspectives. Dermatologic therapy, 33(2), e13247. Available from: https://doi.org/10.1111/dth.13247
  • Paganelli, A., Tarentini, E., Benassi, L., Kaleci, S., & Magnoni, C. (2020). Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review. Clinical and experimental dermatology, 45(7), 824–830. Available from: https://doi.org/10.1111/ced.14269
  • Attia, S. S., Rafla, M., El-Nefiawy, N. E., Abdel Hamid, H. F., Amin, M. A., & Fetouh, M. A. (2021). A potential role of mesenchymal stem cells derived from human umbilical cord blood in ameliorating psoriasis-like skin lesion in the rats. Folia morphologica, 10.5603/FM.a2021.0076. Advance online publication. Available from: https://doi.org/10.5603/FM.a2021.0076
  • Hou, R., Li, J., Niu, X., Liu, R., Chang, W., Zhao, X., Wang, Q., Li, X., Yin, G., & Zhang, K. (2017). Stem cells in psoriasis. Journal of dermatological science, 86(3), 181–186. Available from: https://doi.org/10.1016/j.jdermsci.2016.11.006
  • Kim, K. H., Blasco-Morente, G., Cuende, N., & Arias-Santiago, S. (2017). Mesenchymal stromal cells: properties and role in management of cutaneous diseases. Journal of the European Academy of Dermatology and Venereology : JEADV, 31(3), 414–423. Available from: https://doi.org/10.1111/jdv.13934
  • Owczarczyk-Saczonek, A., Krajewska-Włodarczyk, M., Kruszewska, A., Placek, W., Maksymowicz, W., & Wojtkiewicz, J. (2017). Stem Cells as Potential Candidates for Psoriasis Cell-Replacement Therapy. International journal of molecular sciences, 18(10), 2182. Available from: https://doi.org/10.3390/ijms18102182
  • Chen, M., Peng, J., Xie, Q., Xiao, N., Su, X., Mei, H., Lu, Y., Zhou, J., Dai, Y., Wang, S., Li, C., Lin, G., & Cheng, L. (2019). Mesenchymal Stem Cells Alleviate Moderate-to-Severe Psoriasis by Reducing the Production of Type I Interferon (IFN-I) by Plasmacytoid Dendritic Cells (pDCs). Stem cells international, 2019, 6961052. Available from: https://doi.org/10.1155/2019/6961052
  • Sierra-Sánchez, Á., Montero-Vilchez, T., Quiñones-Vico, M. I., Sanchez-Diaz, M., & Arias-Santiago, S. (2021). Current Advanced Therapies Based on Human Mesenchymal Stem Cells for Skin Diseases. Frontiers in cell and developmental biology, 9, 643125. Available from: https://doi.org/10.3389/fcell.2021.643125
  • Lee, Y. S., Sah, S. K., Lee, J. H., Seo, K. W., Kang, K. S., & Kim, T. Y. (2016). Human umbilical cord blood-derived mesenchymal stem cells ameliorate psoriasis-like skin inflammation in mice. Biochemistry and biophysics reports, 9, 281–288. Available from: https://doi.org/10.1016/j.bbrep.2016.10.002
  • Chen, H., Niu, J. W., Ning, H. M., Pan, X., Li, X. B., Li, Y., Wang, D. H., Hu, L. D., Sheng, H. X., Xu, M., Zhang, L., & Zhang, B. (2016). Treatment of Psoriasis with Mesenchymal Stem Cells. The American journal of medicine, 129(3), e13–e14. Available from: https://doi.org/10.1016/j.amjmed.2015.11.001
  • Lwin, S. M., Snowden, J. A., & Griffiths, C. (2021). The promise and challenges of cell therapy for psoriasis. The British journal of dermatology, 185(5), 887–898. Available from: https://doi.org/10.1111/bjd.20517
  • Lin, Y., Wang, H., Jiang, C., Chen, C., Shen, D., Xie, F., Zhang, H., Yang, J., & Wang, H. (2022). Effects of different concentrations of human umbilical cord mesenchymal stem cells to ameliorate psoriasis-like skin lesions in BALB/c mice. Annals of translational medicine, 10(2), 86. Available from: https://doi.org/10.21037/atm-22-4
  • Shin, T. H., Kim, H. S., Choi, S. W., & Kang, K. S. (2017). Mesenchymal Stem Cell Therapy for Inflammatory Skin Diseases: Clinical Potential and Mode of Action. International journal of molecular sciences, 18(2), 244. Available from: https://doi.org/10.3390/ijms18020244

BioXcellerator Quality: BioXcellerator’s laboratory, has been designed to comply with both regulatory cGMP standards for quality and meet internationally recognized ISO standards that cover safety, air quality, and processing infusions that contain human cells. Disclaimer: Cell therapy offers no guarantees and is not promoted as a cure. This is similar to many other conventional medical treatments but it has scientific support. A review of the patient’s medical history is required to determine eligibility and approval for cell therapy. Any personal information provided is for internal and medical use with our medical providers only. BioXcellerator headquarters is located in Phoenix, Arizona. BioXcellerator Arizona is not a cell treatment facility or surgical center. Treatments are not conducted in our offices or in the U.S.  Since these advanced therapies are not yet approved by the FDA. Like all medical procedures, BioXcellerator procedures have a success and failure rate. Patient reviews and testimonials on this site should not be construed as a statement about the effectiveness of our treatments in general, they are individual perceptions that may or may not apply to everyone.

Copyright © 2023 BioXcellerator Inc | All Rights Reserved | Privacy Policy | Quality Management

Skip to content